KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Notes Payables (2016 - 2025)

AbbVie (ABBV) has disclosed Notes Payables for 14 consecutive years, with $2.5 billion as the latest value for Q4 2025.

  • On a quarterly basis, Notes Payables changed N/A to $2.5 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $2.5 billion, a N/A change, with the full-year FY2025 number at $2.5 billion, changed N/A from a year prior.
  • Notes Payables was $2.5 billion for Q4 2025 at AbbVie, down from $3.8 billion in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $3.8 billion in Q3 2025 to a low of $1.0 million in Q4 2022.
  • A 5-year average of $665.6 million and a median of $14.0 million in 2021 define the central range for Notes Payables.
  • Peak YoY movement for Notes Payables: tumbled 92.86% in 2022, then surged 53000.0% in 2025.
  • AbbVie's Notes Payables stood at $14.0 million in 2021, then crashed by 92.86% to $1.0 million in 2022, then surged by 100.0% to $2.0 million in 2023, then skyrocketed by 50.0% to $3.0 million in 2024, then surged by 83200.0% to $2.5 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Notes Payables are $2.5 billion (Q4 2025), $3.8 billion (Q3 2025), and $2.0 billion (Q2 2025).